Illumina collaborated on a study presented at ASCO 2025 showing that circulating tumor DNA provides actionable data for clinical trials
Illumina bioinformatics solutions prove essential for a Northern Territory genomics program
At ESHG 2025 in Milan, Illumina welcomed customers and industry colleagues to discuss the future of genomic research and health care
NYU Langone Director of Molecular Pathology Matija Snuderl says every brain cancer journey should begin with DNA methylation profiling
Date | Publication | Title |
---|---|---|
Jun 4, 2025 | GenomeWeb | Illumina AI Team Unveils Program to Find Promoter DNA Variants Contributing to Rare Disease |
Jun 2, 2025 | Pharma Outlook | The Future of Genomic Sequencing: Trends That Will Define the Next Decade |
May 29, 2025 | Endpoints News | DNA giant Illumina spawned an ecosystem of competitors and customers |
May 29, 2025 | Medical Device Network | Illumina widens access to cancer tests with Medicare and new CDx |
May 29, 2025 | GenomeWeb | ESHG: Studies Demonstrate Potential of Long-Read Sequencing in Rare Disease Diagnostics |
At Illumina, we push boundaries. We think beyond the conventional. We dream big. With the energy of so many bright and accomplished people, the opportunities are endless.
Search for JobsIf you are a member of the media:
If you are not a member of the media, please visit Contact Us.